{"id":"amoxicillin-high-dose-dual-therapy","safety":{"commonSideEffects":[{"rate":"10%","effect":"Diarrhea"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"5%","effect":"Abdominal pain"},{"rate":"1%","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amoxicillin is a beta-lactam antibiotic that works by inhibiting the synthesis of the bacterial cell wall, ultimately leading to cell lysis and death.","oneSentence":"Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:54:37.545Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections"}]},"trialDetails":[{"nctId":"NCT07352098","phase":"NA","title":"7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori","status":"NOT_YET_RECRUITING","sponsor":"Yueyue Li","startDate":"2026-02-01","conditions":"Helicobacter","enrollment":290},{"nctId":"NCT06734260","phase":"PHASE3","title":"Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Eighth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-09-10","conditions":"Helicobacter Pylori Eradication Rate","enrollment":477},{"nctId":"NCT07232095","phase":"PHASE4","title":"7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-11-30","conditions":"Helicobacter Pylori","enrollment":316},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT07159412","phase":"NA","title":"Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-08-31","conditions":"Helicobacter Pylori Infection, Metabolic-associated Steatohepatitis, High-dose Dual Therapy","enrollment":286},{"nctId":"NCT05742568","phase":"PHASE4","title":"Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-12-01","conditions":"Gastritis, Dyspepsia, Helicobacter Pylori Infection","enrollment":124},{"nctId":"NCT06292546","phase":"NA","title":"The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2024-01-31","conditions":"Gut Microbiota, Metabolic Disturbance, Helicobacter Pylori Eradication","enrollment":72},{"nctId":"NCT03897244","phase":"PHASE4","title":"Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-05-30","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT06881524","phase":"NA","title":"Low-Dose Amoxicillin Dual-Therapy Combined with Licorice and Lotus Root Powder Helicobacter Pylori Treatment","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":374},{"nctId":"NCT06811207","phase":"PHASE3","title":"Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-02-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":300},{"nctId":"NCT06823791","phase":"PHASE1, PHASE2","title":"Furazolidone Quadruple Regimen Eradicate H. Pylori Infection","status":"COMPLETED","sponsor":"Liaocheng People's Hospital","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection, Eradication","enrollment":493},{"nctId":"NCT06777732","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-03","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT05901051","phase":"PHASE4","title":"High-dose Dual Therapy with Different Administration Frequencies","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-30","conditions":"Helicobacter Pylori Infection","enrollment":327},{"nctId":"NCT06561698","phase":"PHASE4","title":"High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT05649540","phase":"PHASE4","title":"Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-01-20","conditions":"Helicobacter Pylori Infection","enrollment":900},{"nctId":"NCT05649709","phase":"PHASE4","title":"Helicobacter Pylori and Vonoprazan Dual Therapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-02-13","conditions":"Helicobacter Pylori","enrollment":504},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT06250634","phase":"NA","title":"Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-10","conditions":"Helicobacter Pylori Infection","enrollment":806},{"nctId":"NCT06412640","phase":"PHASE4","title":"Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-01","conditions":"H. Pylori Infection","enrollment":268},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT05719831","phase":"PHASE3","title":"Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection","status":"COMPLETED","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-01","conditions":"Helicobacter Pylori Eradication Rate","enrollment":516},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT06088316","phase":"PHASE4","title":"Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-02-10","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication","enrollment":70},{"nctId":"NCT05438550","phase":"PHASE4","title":"14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-02-14","conditions":"Helicobacter Pylori Infection","enrollment":258},{"nctId":"NCT05342532","phase":"PHASE4","title":"High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-06-12","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT04678492","phase":"PHASE4","title":"Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastritis, Dyspepsia, Helicobacter Pylori Infection","enrollment":658},{"nctId":"NCT05176821","phase":"NA","title":"Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-01-01","conditions":"H. Pylori Infection","enrollment":186},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT05100446","phase":"EARLY_PHASE1","title":"Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Unidade Local de Saúde do Alto Ave, EPE","startDate":"2021-05-01","conditions":"Helicobacter Pylori Infection, Gastritis, Gastric Cancer","enrollment":100},{"nctId":"NCT04024527","phase":"PHASE4","title":"High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-07-25","conditions":"Helicobacter Pylori Infection","enrollment":306},{"nctId":"NCT03431337","phase":"PHASE4","title":"Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate","status":"TERMINATED","sponsor":"Paul Sorum, MD","startDate":"2018-02-26","conditions":"Sinusitis, Acute","enrollment":157},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT04101708","phase":"PHASE4","title":"A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-09-20","conditions":"Helicobacter Pylori","enrollment":100},{"nctId":"NCT04061447","phase":"NA","title":"Tailored Juice-guided Eradication Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2016-02-05","conditions":"Helicobacter Pylori Infection","enrollment":182},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT03521726","phase":"PHASE4","title":"Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2018-05-11","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT03383003","phase":"NA","title":"Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-03-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT03802318","phase":"NA","title":"Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-02","conditions":"Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer","enrollment":530},{"nctId":"NCT03405584","phase":"PHASE4","title":"High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-03","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT02553083","phase":"PHASE4","title":"High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2015-10-22","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":300},{"nctId":"NCT02401477","phase":"PHASE4","title":"Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2014-12","conditions":"Helicobacter Infections","enrollment":90},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT01265069","phase":"PHASE4","title":"Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-11","conditions":"Helicobacter Pylori Infection","enrollment":204},{"nctId":"NCT01805934","phase":"PHASE2","title":"Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-05","conditions":"Rescue Therapy for Helicobacter Pylori","enrollment":114},{"nctId":"NCT00643292","phase":"PHASE3","title":"A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Acute Otitis Media","enrollment":902},{"nctId":"NCT00197418","phase":"PHASE2, PHASE3","title":"Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection","status":"UNKNOWN","sponsor":"Hamamatsu University","startDate":"2003-08","conditions":"Helicobacter Infections, Gastritis, Gastric Ulcer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Amoxicillin - high dose dual therapy","genericName":"Amoxicillin - high dose dual therapy","companyName":"Unidade Local de Saúde do Alto Ave, EPE","companyId":"unidade-local-de-sa-de-do-alto-ave-epe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}